Brain Magnetic Resonance Imaging (MRI) in Spinal Muscular Atrophy: A Scoping Review.


Journal

Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948

Informations de publication

Date de publication:
2023
Historique:
medline: 11 7 2023
pubmed: 1 5 2023
entrez: 1 5 2023
Statut: ppublish

Résumé

5q Spinal Muscular Atrophy (SMA) is a prototypical lower motor neuron disorder. However, the characteristic early motor impairment raises the question on the scope of brain involvement with implications for further investigations on the brain as a potential therapeutic target. To review changes across the SMA clinical spectrum reported on brain magnetic resonance imaging (MRI). We conducted a scoping review of existing literature on PubMed and EMBASE. Two reviewers searched and retrieved relevant articles on magnetic resonance brain imaging in individuals with SMA censoring to April 2022. Full-text articles published in peer-reviewed journals or abstracts accepted to conferences in English and French were included. Twelve articles were identified describing a total of 39 patients [age range: 11 days to 41 years old, type 0 (n = 5), type 1 (n = 4), type 2 (n = 2), type 3 (n = 22), type 4 (n = 6)]. All reported structural changes and did not explore other MRI modalities. In individuals with infantile onset SMA, cortical and subcortical brain abnormalities in white matter, basal ganglia, thalamus, hippocampus, and high intensity areas around lateral ventricles and thalami were reported over time. In individuals with later-onset SMA, reduced cerebellar and lobular volume were observed as well as increased grey matter density in motor areas. Limited data on brain imaging in SMA highlights both cortical and subcortical involvement in SMA, supporting the hypothesis that changes are not restricted to lower motor neuron pathways. Further studies are needed to determine the extent and prevalence of structural and functional brain changes across SMA types.

Sections du résumé

BACKGROUND BACKGROUND
5q Spinal Muscular Atrophy (SMA) is a prototypical lower motor neuron disorder. However, the characteristic early motor impairment raises the question on the scope of brain involvement with implications for further investigations on the brain as a potential therapeutic target.
OBJECTIVE OBJECTIVE
To review changes across the SMA clinical spectrum reported on brain magnetic resonance imaging (MRI).
METHODS METHODS
We conducted a scoping review of existing literature on PubMed and EMBASE. Two reviewers searched and retrieved relevant articles on magnetic resonance brain imaging in individuals with SMA censoring to April 2022. Full-text articles published in peer-reviewed journals or abstracts accepted to conferences in English and French were included.
RESULTS RESULTS
Twelve articles were identified describing a total of 39 patients [age range: 11 days to 41 years old, type 0 (n = 5), type 1 (n = 4), type 2 (n = 2), type 3 (n = 22), type 4 (n = 6)]. All reported structural changes and did not explore other MRI modalities. In individuals with infantile onset SMA, cortical and subcortical brain abnormalities in white matter, basal ganglia, thalamus, hippocampus, and high intensity areas around lateral ventricles and thalami were reported over time. In individuals with later-onset SMA, reduced cerebellar and lobular volume were observed as well as increased grey matter density in motor areas.
CONCLUSIONS CONCLUSIONS
Limited data on brain imaging in SMA highlights both cortical and subcortical involvement in SMA, supporting the hypothesis that changes are not restricted to lower motor neuron pathways. Further studies are needed to determine the extent and prevalence of structural and functional brain changes across SMA types.

Identifiants

pubmed: 37125560
pii: JND221567
doi: 10.3233/JND-221567
pmc: PMC10357153
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

493-503

Références

Acta Neurol Belg. 2021 Dec;121(6):1883-1885
pubmed: 33079332
Elife. 2021 Aug 23;10:
pubmed: 34423781
J Neuropathol Exp Neurol. 2006 Mar;65(3):267-77
pubmed: 16651888
Brain Dev. 2004 Jan;26(1):53-6
pubmed: 14729416
Neuroimage Clin. 2019;21:101618
pubmed: 30522974
Hum Mol Genet. 2010 Nov 1;19(21):4216-28
pubmed: 20705736
Ann Neurol. 2019 Nov;86(5):801-802
pubmed: 31502271
J Neurol. 2020 Sep;267(9):2625-2631
pubmed: 32388834
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Ann Neurol. 2019 Sep;86(3):458-462
pubmed: 31301241
Neuroscience. 2021 Jan 1;452:78-97
pubmed: 33212215
J Neurosci Res. 2010 Jan;88(1):111-22
pubmed: 19642194
Dis Model Mech. 2017 Aug 1;10(8):943-954
pubmed: 28768735
Acta Neuropathol. 2003 Nov;106(5):441-8
pubmed: 12898156
J Neuropathol Exp Neurol. 2015 Jan;74(1):15-24
pubmed: 25470343
Nat Genet. 1997 Jul;16(3):265-9
pubmed: 9207792
Acta Neuropathol. 1985;65(3-4):270-80
pubmed: 3976363
Neurology. 2010 Nov 2;75(18):1645-52
pubmed: 21041787
Neuromuscul Disord. 2006 Aug;16(8):492-4
pubmed: 16797181
Dev Med Child Neurol. 2021 May;63(5):527-536
pubmed: 33452688
Cell Mol Life Sci. 2018 Nov;75(21):3877-3894
pubmed: 29872871
Cerebellum. 2012 Jun;11(2):457-87
pubmed: 22161499
Ann Neurol. 1996 Nov;40(5):731-8
pubmed: 8957014
Neuropathology. 2009 Feb;29(1):63-7
pubmed: 18410269
Rev Neurol (Paris). 1999 Sep;155(8):589-91
pubmed: 10486849
J Comp Neurol. 2006 Aug 10;497(5):808-16
pubmed: 16786553
Pediatr Neurol. 1995 May;12(4):365-9
pubmed: 7546013

Auteurs

Nancy Mugisha (N)

Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Andrea Oliveira-Carneiro (A)

Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Tarannum Behlim (T)

Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Maryam Oskoui (M)

Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Departments of Pediatrics and Neurology Neurosurgery, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH